Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2341-2346

  Jensen, L H ^a   Lindebjerg, J ^a   Ploen, J ^a   Hansen, T F ^a   Jakobsen, A ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biliary tract cancer; Chemotherapy; Cholangiocarcinoma; KRAS; Marker driven treatment; Panitumumab

Indexed keywords

CAPECITABINE; GEMCITABINE; OXALIPLATIN; PANITUMUMAB; TUMOR MARKER;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; INOPERABLE CANCER; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYSTEMIC THERAPY; TREATMENT DURATION; WILD TYPE;

EID: 84863719528     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds008     Document Type: Article

References (27)

1. de G, Gores G, LaRusso N, Gunderson L, Nagorney D. Biliary tract cancers. N Engl J Med 1999; 341(18): 1368-1378.
2. Gatto M, Bragazzi MC, Semeraro R et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42(4): 253-260.
3. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96(6): 896-902.
4. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362(14): 1273-1281.
5. Lassen U, Jensen LH, Sorensen M et al. A phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. Acta Oncol 2011; 50(3): 448-454.
6. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22(7): 1201-1208.
7. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-1664.
8. Nakazawa K, Dobashi Y, Suzuki S et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206(3): 356-365.
9. Jimeno A, Rubio-Viqueira B, Amador ML et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005; 65(8): 3003-3010.
10. Chang PY, Cheng MF, Lee HS et al. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie 2010; 33(1-2): 45-47.
11. Huang TW, Wang CH, Hsieh CB. Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. Onkologie 2007; 30(3): 129-131.
12. Sprinzl M, Schimanski C, Moehler M et al. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer 2006; 6190.
13. Bralet MP, Bellin MF, Guettier C et al. Response to cetuximab and gemcitabineoxaliplatin in an advanced case of intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol) 2006; 18(5): 426.
14. Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007; 72(1-2): 105-110.
15. Giusti RM, Shastri K, Pilaro AM et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14(5): 1296-1302.
16. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-1634.
17. ICH Topic E 6 (R1) Guideline for Good Clinical Practice [Internet] 1997 http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/ 09/WC500002874.pdf (24 January 2012, date last accessed).
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
19. Tannapfel A, Sommerer F, Benicke M et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52(5): 706-712.
20. Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11(12): 1142-1148.
21. Xu RF, Sun JP, Zhang SR et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 2011; 65(1): 22-26.
22. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28(31): 4697-4705.
23. Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma. http://clinicaltrials.gov/ct2/show/NCT00779454 (24 January 2012, date last accessed).
24. Jensen LH, Jakobsen A. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther 2011; 11(4): 589-600.
25. Malka D, Trarbach T, Fartoux L et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol (Meeting Abstracts) 2009; 27(15S): 4520.
26. Lee J, Park SH, Chang HM et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 21 December 2011 [epub ahead of print], doi:10.1016/S1470-2045(11)70301-1.
27. Jensen LH. Biliary-tract cancer: improving therapy by adding molecularly targeted agents. Lancet Oncol 21 December 21, 2011 [epub ahead of print], DOI:10.1016/S1470-2045(11)70329-1.